Sunday, March 05, 2023 4:46:08 PM
If the case is made that spoofing cost shareholders somewhere in the $1 to $2 a share, so a $1 to $2 billion figure could be arrived at by a jury, I believe the bigger question could be, does the jury apply a substantial penalty to the actions of the MM's. I've got to believe the Attorneys would ask for a large penalty, and that's a risk the MM's take if they let it go to trial. Could the jury decide to really punish those responsible would a double digit billion award be possible, I think so. Of course this may not happen, they might not award a billion or more, I don't think you can ever be certain of what a jury will do.
I believe that in a settlement the attorney's percentage may not be quite as great as if they go to trial, but if it settles they'll probably spend far less time, so that's a fair outcome. Regardless they'd probably get at least 20% or more, so it certainly would be worth their time.
My point in settling soon would be that they can really use a few hundred million now. I believe that LP can get the job done with, or without it, but it would be easier with it. By the same token she's the type of person who tends to roll the dice, so I don't know she won't go for the jury and believe with their case they'll award a big penalty.
Gary
I believe that in a settlement the attorney's percentage may not be quite as great as if they go to trial, but if it settles they'll probably spend far less time, so that's a fair outcome. Regardless they'd probably get at least 20% or more, so it certainly would be worth their time.
My point in settling soon would be that they can really use a few hundred million now. I believe that LP can get the job done with, or without it, but it would be easier with it. By the same token she's the type of person who tends to roll the dice, so I don't know she won't go for the jury and believe with their case they'll award a big penalty.
Gary
Bullish
Recent NWBO News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
